Sunil Kalla

Suggest Changes
Learn More
BACKGROUND The best therapeutic strategy for patients with double-vessel coronary artery disease and proximal left anterior descending artery involvement (2VD + pLAD) is not clear. OBJECTIVES To(More)
7090 Background: We previously reported the preliminary activity and tolerability of the combination of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) and docetaxel in patients with(More)
5015 Background: EGFR expression is increased in 35-70% of primary OC, and often correlates with poor prognosis. Gefitinib (Iressa, ZD1839) is an orally active EGFR-TKI (epidermal growth factor(More)